Several classes of medication can slow kidney function decline, and in some cases, the combination of two or three of them offers stronger protection than any single drug alone. The most well-established options target blood pressure regulation inside the kidneys, excess sugar filtering, inflammation, and scarring. Which ones your doctor considers depends on the underlying cause of kidney damage, your current level of kidney function, and whether you have diabetes or heart failure.
Blood Pressure Drugs That Protect the Kidneys
ACE inhibitors and ARBs have been the backbone of kidney protection for decades. These medications work by relaxing a specific blood vessel inside the kidney called the efferent arteriole. When this vessel relaxes, pressure inside the kidney’s filtering units drops. That matters because high filtering pressure is one of the main forces that damages kidneys over time, especially when protein is leaking into the urine.
By lowering that internal pressure, these drugs reduce the amount of protein spilling into urine, a key marker of ongoing kidney damage. They’re typically the first medication prescribed when blood or urine tests show early signs of kidney disease, particularly in people with diabetes or high blood pressure. Common examples include lisinopril, ramipril, and losartan.
One thing to expect: your kidney function numbers on blood tests may dip slightly when you first start one of these drugs. This reflects the intended drop in filtering pressure, not actual harm. Doctors monitor bloodwork in the first few weeks to make sure the change stays within a safe range. A modest early dip is generally a sign the medication is doing its job.
SGLT2 Inhibitors: A Major Shift in Kidney Care
Originally developed to lower blood sugar in type 2 diabetes, SGLT2 inhibitors turned out to be one of the most significant kidney-protective drugs discovered in years. They work by blocking the kidney from reabsorbing sugar back into the bloodstream, but that mechanism triggers a cascade of beneficial effects: lower pressure inside the filtering units, reduced inflammation, and less strain on kidney tissue.
A large meta-analysis found that SGLT2 inhibitors reduced the risk of chronic kidney disease progression by 38% overall and lowered the risk of kidney failure by 34%. These benefits held across nearly every stage of kidney disease, including people with stage 4 CKD (severely reduced function) and those with only minimal protein in their urine. The protection also extended to people without diabetes, which led to these drugs being approved for CKD broadly, not just in diabetic kidney disease.
SGLT2 inhibitors also slow the annual rate of kidney function decline regardless of where you start. That means even if your kidneys are already significantly impaired, these medications can help preserve what’s left. Dapagliflozin and empagliflozin are the two most commonly prescribed in this class for kidney protection.
Finerenone for Inflammation and Scarring
Finerenone is a newer medication that blocks a hormone receptor involved in kidney inflammation and scarring. When this receptor is overactivated, it drives a cycle of tissue damage that accelerates kidney decline. Finerenone interrupts that cycle by reducing both inflammatory and fibrotic signals in kidney tissue.
In clinical trials involving patients with type 2 diabetes and kidney disease, finerenone reduced protein leakage in urine by 32% compared to placebo within four months. Patients on the drug were also 82% more likely to see their urine protein levels drop back to a lower, less dangerous category over time. These are meaningful shifts because the amount of protein in urine is one of the strongest predictors of how quickly kidney disease will worsen.
Finerenone is currently approved for people with type 2 diabetes and chronic kidney disease. It’s designed to be used alongside ACE inhibitors or ARBs, not as a replacement, adding a second layer of protection on top of blood pressure control.
GLP-1 Receptor Agonists
GLP-1 receptor agonists, best known as weight loss and diabetes medications (semaglutide is the most recognized), also protect the kidneys. The FLOW trial, published in the New England Journal of Medicine, found that semaglutide reduced the risk of major kidney events by 24% in people with type 2 diabetes and chronic kidney disease. These events included significant drops in kidney function, kidney failure, and kidney-related death.
The kidney benefits appear to come from a combination of effects: lower blood sugar, reduced blood pressure, weight loss, and direct anti-inflammatory action on kidney tissue. For people who have both type 2 diabetes and declining kidney function, a GLP-1 agonist may complement other kidney-protective medications.
How These Medications Work Together
The current approach to protecting kidney function often involves layering two or more of these drug classes. Each one targets a different mechanism of kidney damage. ACE inhibitors or ARBs lower filtering pressure. SGLT2 inhibitors reduce metabolic strain and pressure through a separate pathway. Finerenone addresses inflammation and scarring. GLP-1 agonists add metabolic and anti-inflammatory benefits on top.
Not everyone needs all four. A person with early-stage kidney disease and well-controlled blood pressure might start with an ACE inhibitor and an SGLT2 inhibitor. Someone with type 2 diabetes, significant protein in their urine, and progressive disease might benefit from adding finerenone or a GLP-1 agonist as well. The decision depends on how aggressive the kidney disease is and what other conditions are present.
Managing Side Effects That Threaten Treatment
The biggest practical barrier to staying on kidney-protective medications is elevated potassium. ACE inhibitors, ARBs, and finerenone all raise potassium levels to some degree, and high potassium can cause dangerous heart rhythm problems. This side effect historically forced many patients to reduce their dose or stop these drugs entirely, sacrificing kidney protection.
Newer potassium-lowering medications have changed that equation. Drugs like patiromer and sodium zirconium cyclosilicate bind excess potassium in the gut and remove it from the body. A meta-analysis found these medications lowered potassium levels by an average of 0.71 mEq/L and reduced episodes of dangerously high potassium by 28%. More importantly, they increased the proportion of patients who could stay on full-dose kidney-protective therapy by 38%. For people with CKD specifically, the improvement was even larger at 84%.
This means that if you’ve been told to lower your dose of an ACE inhibitor or ARB because of high potassium, a potassium binder may allow you to resume the full protective dose. It’s a supporting medication that doesn’t directly help the kidneys but enables the drugs that do.
What These Medications Cannot Do
All of these drugs slow kidney decline. None of them reverse established damage. Kidney tissue that has scarred over does not regenerate, so the goal is preservation: keeping your current level of function as stable as possible for as long as possible. Starting earlier, when there’s more function left to protect, produces better long-term outcomes than waiting until kidney disease is advanced.
These medications also work best alongside the basics: blood pressure control, blood sugar management if you have diabetes, adequate hydration, and limiting use of over-the-counter painkillers like ibuprofen and naproxen that stress the kidneys. Medication is one layer of protection, not a substitute for the others.